within Pharmacolibrary.Drugs.D_Dermatologicals.D01A_AntifungalsForTopicalUse.D01AC19_Efinaconazole;

model Efinaconazole
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 4.5e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.0362,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Efinaconazole</td></tr><tr><td>ATC code:</td><td>D01AC19</td></tr><td>route:</td><td>topical</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>36.2</td><td>L</td></tr>
    <tr><td>clearance:</td><td>16.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Efinaconazole is a triazole antifungal agent primarily indicated for the topical treatment of onychomycosis (fungal infection) of the toenails. It is approved for use in various countries and is currently available as a prescription medication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for topical application in healthy adult subjects; limited systemic absorption observed after application to the toenails.</p><h4>References</h4><ol><li><p>Eichenfield, LF, et al., &amp; Guenin, E (2020). Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients. <i>Journal of drugs in dermatology : JDD</i> 19(9) 867–872. DOI:<a href=\"https://doi.org/10.36849/JDD.2020.10.36849/JDD.2020.5401\">10.36849/JDD.2020.10.36849/JDD.2020.5401</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33026753/\">https://pubmed.ncbi.nlm.nih.gov/33026753</a></p></li><li><p>Gupta, AK, et al., &amp; Cooper, EA (2024). Efinaconazole 10% solution: a comprehensive review of its use in the treatment of onychomycosis. <i>Expert opinion on pharmacotherapy</i> 25(15) 1983–1998. DOI:<a href=\"https://doi.org/10.1080/14656566.2024.2416924\">10.1080/14656566.2024.2416924</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39394930/\">https://pubmed.ncbi.nlm.nih.gov/39394930</a></p></li><li><p>Gregoriou, S, et al., &amp; Rigopoulos, D (2022). Novel and Investigational Treatments for Onychomycosis. <i>Journal of fungi (Basel, Switzerland)</i> 8(10) –. DOI:<a href=\"https://doi.org/10.3390/jof8101079\">10.3390/jof8101079</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36294644/\">https://pubmed.ncbi.nlm.nih.gov/36294644</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D01AC19 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Efinaconazole;
